XML 94 R77.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information - Reportable Segment Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Net sales $ 11,484 $ 11,479 $ 12,440
Cost of sales (7,360) (7,798) (8,289)
Research & development expenses (671) (636) (603)
Selling & administrative expenses (1,995) (1,787) (1,768)
Income (loss) before taxes 278 (2,518) (1,625)
Depreciation and amortization (1,015) (1,142) (1,179)
Interest expense (305) (380) (336)
Other (expense) income, net (182) (5) 26
Additional charges, net 29 68 12
Goodwill, impairment loss (64) (2,623) (2,250)
(Losses) gains on business divestitures 346 (23) 11
Loss on assets classified as held for sale (347) 0 0
Acquisition, divestiture and integration costs (228) (174) (201)
Strategic Initiatives Costs (33) (31) (8)
Regulatory fees (73) (50)  
Other 3 (2) (11)
Impairment, Long-Lived Asset, Held-for-Use 0 0 (120)
Business divestiture costs 223 108 110
Business integration costs 5 59 94
Acquisition related costs   7 (3)
Pension Plan | Non-U.S. Plans      
Segment Reporting Information [Line Items]      
Settlement gain (loss) 1 8 0
Pension Plan | Non-U.S. Plans | International Flavors & Fragrances Inc. Pension Plan      
Segment Reporting Information [Line Items]      
Settlement gain (loss) (130)    
Nourish      
Segment Reporting Information [Line Items]      
Additional charges, net 26 37 8
Goodwill, impairment loss   (2,623)  
Health & Biosciences      
Segment Reporting Information [Line Items]      
Additional charges, net 1 13 2
Goodwill, impairment loss   0  
Scent      
Segment Reporting Information [Line Items]      
Additional charges, net 1 15 1
Goodwill, impairment loss   0  
Pharma Solutions      
Segment Reporting Information [Line Items]      
Additional charges, net 1 3 1
Goodwill, impairment loss (64) 0  
Operating Segments      
Segment Reporting Information [Line Items]      
Net sales 11,484 11,479 12,440
Segment Adjusted Operating EBITDA 2,205 1,980 2,455
Operating Segments | Nourish      
Segment Reporting Information [Line Items]      
Net sales 5,871 6,060 6,829
Cost of sales (4,147) (4,517) (4,827)
Research & development expenses (220) (216) (211)
Selling & administrative expenses (878) (822) (853)
Depreciation expense add-back 198 227 238
Segment Adjusted Operating EBITDA 824 732 1,176
Operating Segments | Health & Biosciences      
Segment Reporting Information [Line Items]      
Net sales 2,212 2,081 2,339
Cost of sales (1,182) (1,170) (1,361)
Research & development expenses (188) (170) (166)
Selling & administrative expenses (302) (266) (282)
Depreciation expense add-back 114 113 104
Segment Adjusted Operating EBITDA 654 588 634
Operating Segments | Scent      
Segment Reporting Information [Line Items]      
Net sales 2,440 2,393 2,301
Cost of sales (1,359) (1,400) (1,390)
Research & development expenses (218) (202) (189)
Selling & administrative expenses (412) (390) (353)
Depreciation expense add-back 67 60 54
Segment Adjusted Operating EBITDA 518 461 423
Operating Segments | Pharma Solutions      
Segment Reporting Information [Line Items]      
Net sales 961 945 971
Cost of sales (654) (698) (701)
Research & development expenses (24) (24) (23)
Selling & administrative expenses (99) (86) (81)
Depreciation expense add-back 25 62 56
Segment Adjusted Operating EBITDA $ 209 $ 199 $ 222